Hillsdale Investment Management Inc. Makes New $3.90 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD

Hillsdale Investment Management Inc. bought a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,156,378 shares of the biotechnology company’s stock, valued at approximately $3,897,000. Hillsdale Investment Management Inc. owned 0.71% of Ironwood Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of IRWD. Integrated Wealth Concepts LLC raised its holdings in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 3,406 shares during the period. LSV Asset Management acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter worth $30,000. Captrust Financial Advisors acquired a new stake in Ironwood Pharmaceuticals in the second quarter worth $32,000. Simplify Asset Management Inc. acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter worth $37,000. Finally, Vise Technologies Inc. acquired a new stake in Ironwood Pharmaceuticals in the third quarter worth $39,000.

Ironwood Pharmaceuticals Stock Performance

IRWD stock opened at $3.57 on Monday. The stock has a 50-day moving average price of $3.80 and a two-hundred day moving average price of $3.86. The stock has a market cap of $582.12 million, a PE ratio of 5.95 and a beta of 0.25. Ironwood Pharmaceuticals, Inc. has a 1 year low of $0.56 and a 1 year high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The firm had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. On average, analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current fiscal year.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, Director Alexander J. Denner sold 6,730,800 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total value of $20,528,940.00. Following the sale, the director directly owned 9,188,635 shares in the company, valued at approximately $28,025,336.75. The trade was a 42.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IRWD shares. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. Citizens Jmp increased their target price on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $3.70 target price on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Ironwood Pharmaceuticals presently has an average rating of “Hold” and an average price target of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.